Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-lb1-07
Abstract: Background: In the phase 3 KEYNOTE-522 (NCT03036488) study, neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) with adjuvant pembro significantly improved pCR, event-free survival (EFS) and OS vs neoadjuvant placebo (pbo) + chemo with adjuvant pbo in… read more here.
Keywords: pbo chemo; chemo; pembrolizumab; pembro chemo ... See more keywords
Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.4073
Abstract: 4073 Background: Pathologic tumor downstaging (pDS) is more accurate than clinical staging for prognosis; generally, patients (pts) with downstaged tumors have lower recurrence rates and improved overall survival (OS). mPR is an important surrogate end… read more here.
Keywords: chemo; pbo chemo; pbo; keynote 585 ... See more keywords